PRAX · Praxis Precision Medicines, Inc.
AI read · Good for PRAX
The AI's read
A stronger analyst view can help investors see more promise in Praxis. But the report does not say that a treatment trial or the company's sales changed.
Wells Fargo moved its Praxis rating from Equalweight to Overweight and set a $509 share-price target. That supports a favorable read, though the report gives no new trial or sales results.
A stronger analyst view can help investors see more promise in Praxis. But the report does not say that a treatment trial or the company's sales changed.
Follow Praxis Precision Medicines, Inc. (PRAX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PRAX